Praxis Precision Medicines, Inc. PRAX 深 滬
已收盤 01-09 16:00:00 美东时间
288.45
-5.930
-2.01%
華盛通- 最 高305.21
- 今 開291.96
- 成交量 68.88万股
- 最 低 285.99
- 昨 收 294.38
- 總市值 60.72亿
- 52周最高 317.72
- 市盈率 靜 --
- 換手率 3.27%
- 52周最低 26.70
- 委 比 68.07%
- 總股本 2104.96万
- 歷史最高 914.265
- 量 比 1.14
- 振 幅 6.53%
- 歷史最低 11.85
- 每 手 1
- 風險率 76.52%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Praxis Precision prices $575M stock offering at $260
Clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders, Praxis Precision Medicines (PRAX) priced its underwritte...
01-07 12:48
Praxis Precision Medicines announces proposed public stock offering
Praxis Precision Medicines (PRAX) announced a proposed public offering of its common stock and, for certain investors, pre-funded warrants in lieu of common stock. All securities in the offering will ...
01-07 05:09
Praxis Precision Medicines Announces Proposed Public Offering; No Terms Disclosed
Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by
01-07 05:05
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
Praxis Precision Medicines announced a proposed public offering of its common stock and pre-funded warrants to certain investors. The offering includes an option for underwriters to purchase additional shares. Piper Sandler, TD Cowen, Guggenheim Securities, and Truist Securities are leading the offering. The offering is subject to market conditions and SEC filing.
01-06 21:03
美股牛股 | Sidus Space涨超33%，完成发行1620万美元股份；DigitalBridge涨近10%
Sidus Space涨超33%，完成发行1620万美元股份，此前获国防部合同；SLS涨超16%，关键实验取得积极进展；DigitalBridge涨近10%，获软银40亿美元收购>>
2025-12-30 14:43
美股大行评级 | 潜在涨幅908.06%！Piper Sandler首予Palisade Bio(PALI)"超配"评级，目标价25美元
今日重点评级关注：Needham：维持Autolus Therapeutics"买入"评级，目标价从10美元升至11美元；BTIG：维持Praxis Precision Medicine"买入"评级，目标价从507美元升至843美元
2025-12-30 10:04
BTIG将PRXV列为2026年首选标的 目标价从507美元上调至843美元
临床阶段生物制药公司Praxis Precision Medicines（PRXV）周一盘前上涨逾2%，此前BTIG将其股票列为2026年首选标的，并上调了...
2025-12-29 21:50
Praxis Wins FDA Breakthrough Status for Ulixacaltamide
The latest announcement is out from Praxis Precision Medicines ( ($PRAX) ). On ...
2025-12-29 21:28
BTIG Maintains Buy on Praxis Precision Medicine, Raises Price Target to $843
BTIG analyst Kambiz Yazdi maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $507 to $843.
2025-12-29 18:42
Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor
Praxis announced FDA granted Breakthrough Therapy Designation for ulixacaltamide, a T-type calcium channel inhibitor, for essential tremor (ET) based on positive Phase 3 results. The company completed a pre-NDA meeting with FDA and plans to submit NDA in early 2026. ET affects millions, with limited treatment options, highlighting the need for better therapies. Ulixacaltamide aims to address neuronal imbalance linked to tremors.
2025-12-29 13:00
